SER-109 | Friends of Cancer Research

You are here

SER-109

Sponsor: 
Seres Therapeutics, Inc.
Indication: 
Recurrent C. difficile infection
Year: 
2019
Date: 
Apr 29th
FDA Status: 
Designation Granted